🔬 Third-party verified peptides · Free Express Post over $200 CAD
Pantheon Peptides
Libido5 cited studies

Melanotan 2

Synthetic α-MSH analog — non-selective melanocortin agonist studied for pigmentation, libido, appetite.

Also known as: Melanotan II · MT-2 · MT2
SummaryMechanismDosingSafetyStudies
Research use only — not for human consumption.

What it is

Melanotan 2 (MT-2) is a synthetic peptide that mimics α-melanocyte-stimulating hormone (α-MSH). It is best known for stimulating melanin production and skin pigmentation, with secondary research interest in sexual function and appetite control. Effects are downstream of broad melanocortin receptor activation (MC1, MC3, MC4, MC5).

Mechanism of action

Non-selective melanocortin receptor agonist. MC1 activation drives melanin synthesis; MC4 activation underlies sexual arousal and appetite suppression; MC3/5 contribute to lipid and immune effects.

Half-life: ~30 minutes to a few hours, with prolonged tissue effects on pigmentation.

Evidence summary

Pilot Phase 1 work (1996) characterised the cyclic peptide pharmacology. Subsequent trials in psychogenic ED (1998), preformulation work, and recent appetite/dermatology research extend the profile, though MT-2 is unapproved.

Typical dosing protocols

Typical dose
250–500 mcg
Frequency
2x per week
Cycle length
4 weeks
  • Loading: 250–500 mcg subcutaneous daily until pigmentation onset
  • Maintenance: 250–500 mcg, 1–3× weekly
  • Apply standard sun-exposure for activation

Side effects & safety

  • Nausea, flushing, appetite suppression early in cycle
  • Spontaneous erections / yawning common (MC4 effects)
  • Risk of new or darkening moles — dermatology monitoring advised
Contraindications
  • • Personal or family history of melanoma
  • • Multiple atypical nevi

Cited studies

  1. (1996). Evaluation of Melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sciences (ScienceDirect).
    Read source ↗
  2. (1998). Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. Journal of Urology.
    Read source ↗
  3. (1994). Preformulation studies with melanotan-II: a potential skin cancer chemopreventive peptide. Journal of Pharmaceutical Sciences.
    Read source ↗
  4. (2022). Melanocortin receptor agonist melanotan-II microinjected in the nucleus accumbens decreases appetitive and consumptive responding for food. Neuropeptides.
    Read source ↗
  5. (2021). Melanotan II User Experience: A Qualitative Study of Online Discussion Forums. Dermatology.
    Read source ↗
Disclaimer

All content is for research and educational purposes. Peptides described are sold for laboratory research use only and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare professional before beginning any protocol.